EP0955947B1 - Pharmaceutical delivery system - Google Patents
Pharmaceutical delivery system Download PDFInfo
- Publication number
- EP0955947B1 EP0955947B1 EP98900505A EP98900505A EP0955947B1 EP 0955947 B1 EP0955947 B1 EP 0955947B1 EP 98900505 A EP98900505 A EP 98900505A EP 98900505 A EP98900505 A EP 98900505A EP 0955947 B1 EP0955947 B1 EP 0955947B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- delivery system
- delivery
- housing
- arm
- gap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 26
- 210000003491 skin Anatomy 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 210000004207 dermis Anatomy 0.000 claims description 4
- 210000002615 epidermis Anatomy 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 229940090046 jet injector Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 description 20
- 229960005486 vaccine Drugs 0.000 description 19
- 229940079593 drug Drugs 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000012266 Needlestick injury Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940028582 micotil Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000223 tilmicosin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D9/00—Bandages, poultices, compresses specially adapted to veterinary purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
Definitions
- the present invention relates to the administration of drugs or vaccines to vertebrate subjects. More particularly, the invention relates to a pharmaceutical delivery system for use with a variety of delivery devices, wherein the system prevents, or reduces the incidence of, inappropriate or accidental administration of a drug or vaccine to a person operating the delivery system.
- Drugs and vaccines are routinely administered to vertebrate subjects by needle and syringe, and the accidental administration of drugs or vaccines to technicians, for example by needle stick, is not uncommon. Devices that deliver drugs or vaccines via air injection, jet injection or particle bombardment can also be accidently discharged, thereby delivering a drug or vaccine to an inappropriate recipient. The administration of veterinary drugs and vaccines is often carried out under less than ideal conditions, which greatly increases the potential for such inappropriate administrations.
- WO90/13270 describes a medicated ear tag.
- FR-A-2599976 describes a transdermal therapeutic device.
- a vaccine intended to prevent reproductive maturation in a domestic animal could, if accidently administered to a human, prevent reproductive maturation in the human.
- EP-A-376 143 discloses a device for prolonged medicine application corresponding the preamble of claim 1 of the invention.
- the invention relates to a pharmaceutical delivery system.
- the delivery system has first and second substantially planar opposing arms that are connected to each other at one end of a housing, and open at an opposite end to define a gap.
- the gap is sized to receive a body part of a vertebrate.
- a delivery means is disposed on one of the opposing arms of the housing, and is capable of delivering a pharmaceutical to a vertebrate body part inserted within the gap. Delivery of the pharmaceutical is carried out along a direction substantially normal to the plane of the opposing arms.
- the invention relates to a pharmaceutical delivery system
- a pharmaceutical delivery system comprising a housing formed from opposing arms that are held together by a dynamic fastener at a closed end of the housing. At an opposite end of the housing, the arms are open to define a gap into which a vertebrate body part can be inserted for administration of a pharmaceutical.
- the system also includes a delivery means arranged on one arm. A pharmaceutical can be delivered from the delivery means to a vertebrate body part disposed within the housing.
- the gaps provided at the open ends of the system housings are preferably sized to accommodate a skin flap, ear, tail, fin or wing of a vertebrate, but small enough to reduce the possibility of accidently inserting an adult human appendage into the gap.
- the delivery systems can employ any known pharmaceutical delivery mechanism, such as, but not limited to, a needle syringe, an air injector, a jet injector or a particle injector.
- the above pharmaceutical delivery systems can also include means for applying tracking indicia on body parts inserted within the system housings.
- Such indicia can include dye marks, tattoos, scars, brands, tags, or fin or ear notches.
- the delivery systems can further include means for positioning and maintaining a vertebrate body part within the delivery system, such as mechanical, hydraulic, inflatable, or other adjustable means that reduce the size of the gap provided by the opposing arms of the housing.
- a "pharmaceutical” intends any compound or composition of matter which, when administered to a vertebrate subject, induces a desired pharmacologic, immunologic, and/or physiologic effect by local and/or systemic action.
- the term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, growth promotants, and biopharmaceuticals, including, without limitation: proteins, peptides and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced); nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) including both double- and single-stranded molecules, gene constructs, and expression vectors); carbohydrates; polysaccharides; growth promoting or enhancing steroids and chemicals; steroid and non-steroid hormones; cytokines and other biological response modifiers and/or intercellular messengers; and the like.
- the term "pharmaceutical” includes compounds or compositions for use in all of the major therapeutic areas, and is particularly defined herein to include vaccine compositions containing an antigen capable of initiating lymphocyte activation resulting in an antigen-specific immune response, adjuvants, immunomodulators, cytokines, and the like.
- vertebrate subject a member of the subphylum chordata, including, without limitation, mammals such as rodents, cattle, pigs, sheep, goats, horses and non-human primates; domestic animals such as dogs and cats; birds, including domestic, wild and game birds such as cocks and hens including chickens, turkeys and other gallinaceous birds; and fish.
- mammals such as rodents, cattle, pigs, sheep, goats, horses and non-human primates
- domestic animals such as dogs and cats
- birds, including domestic, wild and game birds such as cocks and hens including chickens, turkeys and other gallinaceous birds
- fish does not denote a particular age. Thus, adults, newborns, and fetuses are intended to be covered.
- the delivery system includes a housing 4 , having first and second substantially planar opposing arms, 6 and 8, respectively, connected to each other at a closed end 10 of the housing 4.
- the opposing arms are open at an end 12 opposite from the closed end 10 , thereby defining a gap 14 into which a vertebrate body part can be inserted.
- the gap is sized to receive a skin flap, ear, tail, fin, or wing of a vertebrate.
- the housing 4 can be comprised of any suitable material, for example a resilient metal or polymeric material, and can be formed by conventional methods such as casting, injection molding, milling, or the like.
- the housing has an overall shape and outer dimension designed to fit comfortably within an operator's grasp to facilitate single-hand operation of the delivery system.
- the delivery system 2 comprises a protrusion or extension attached to the housing 4 that enables the delivery system to be operated from a more remote location.
- Suitable protrusions include handles or grips, and suitable extensions for use in the invention include, but are not limited to, wands, booms or poles.
- the extension can have an adjustable length, such as wherein the extension is a telescoping pole, or the like.
- opposing arms 6 and 8 are fixed relative to each other such that the size of the gap 14 does not change appreciably during operation of the device.
- the housing 4 can be partially inflatable.
- the housing When in a deflated state, the housing can be readily positioned about an vertebrate's body part. Once in place, the housing can be inflated to hold the body part in position for subsequent delivery of a drug or vaccine from the delivery system 2 .
- the partially inflatable housing includes structural elements that maintain the overall shape of the housing, and deformable or elastic elements that allow the structure to be inflated and deflated within a selected range.
- the partially inflatable housing further comprises means for communicating with a source of compressed gas, for example a valve body or the like.
- the ability to hold the body part in position using the inflatable housing provides a higher degree of control over the delivery of the pharmaceutical.
- tissue into which the pharmaceutical is to be delivered can be substantially stabilized at a selected pressure, and a targeted delivery area will not be brought out of its position within the device due to movements by the vertebrate subject or the operator.
- the delivery system 2 includes a delivery means 16 arranged on the housing arm 6 at a selected position proximal to the closed end 10 of the housing.
- the present delivery system is designed for use with any type of pharmaceutical delivery means known in the art, for example, conventional needle syringes, spring or compressed gas (air) injectors (U.S. Patent Nos. 1,605,763 to Smoot; 3,788,315 to Laurens; 3,853,125 to Clark et al.; 4,596,556 to Morrow et al.; and 5,062,830 to Dunlap), liquid jet injectors (U.S. Patent Nos.
- the delivery means 16 can be used for single use delivery of a pharmaceutical, such as wherein the delivery system 2 is a disposable unit.
- the delivery means can be used for repeated delivery, in which case a controlled or metered supply of pharmaceutical and/or motive force (e.g., compressed gas) can be associated with the delivery system, either remotely or directly, by way of a suitable interface.
- a plurality of discrete delivery means can be employed within the housing, such as wherein it is desirable to simultaneously deliver a number of different pharmaceuticals to the vertebrate subject using a single delivery system.
- the delivery system can be configured to provide at least a partial vacuum with a body part inserted into the housing.
- a delivery system 2' having a first delivery means 16' on one opposing arm 6' of the housing 4' , and a second delivery means 20 disposed on the other opposing arm 8' .
- the first and second delivery means can be positioned such that they substantially oppose each other across the interior of the housing, or the delivery means can be positioned such that they are offset from each other.
- the delivery means 16 is used to deliver a pharmaceutical to a vertebrate body part placed within the gap 14 at the open end 12 of the housing 4 .
- Parenteral delivery of the pharmaceutical is generally preferred, for example wherein the pharmaceutical is delivered into muscle tissue, dermis, epidermis, or subcutaneous space of the vertebrate body part inserted into the housing.
- Other modes of delivery can also be practiced, such as topical delivery from the delivery means.
- delivery of the pharmaceutical is carried out within the housing, and proceeds in a transverse direction relative to the plane of the opposing arms 6 and 8 of the housing. More particularly, the direction of pharmaceutical delivery is generally within the range of about 5 to about 90 degrees relative to the plane of the opposing arms.
- the delivery means can be configured to deliver the pharmaceutical into the dermis, epidermis or subcutaneous space of the body part.
- the delivery means 16 can also be adjusted within the above range when switching between different modes of delivery with the delivery system 2 .
- the direction of delivery can be set substantially normal to the plane of the opposing arms.
- the direction of delivery can be reset closer to about 5 degrees relative to the plane of the opposing arms.
- the selected angle or direction of delivery from the delivery means 16 will depend upon the mode of delivery used, and can be readily determined by those of ordinary skill in the art.
- the gap 14 defined by the opposing arms of the housing can be dimensioned to readily receive a skin flap, ear, tail, fin or wing (e.g., a wing web) of a vertebrate, but help prevent accidental insertion of a human appendage into the gap. More particularly, the gap 14 at the open end 12 of the housing has a small enough width (w) to preclude insertion of human fingers into the body of the housing, thus preventing contact with the delivery means which could lead to inadvertent delivery of the pharmaceutical to a human operator or technician.
- w small enough width
- an additional level of protection can be provided by arranging the delivery means 16 at, or near to, the closed end 10 of the housing 4 .
- the distance (l), between the open end 14 of the housing and the delivery means 16, is sufficiently long enough to prevent a human appendage inserted into the gap 14 from contacting the delivery means.
- Yet further safety features that can be added to the delivery system 2 include, but are not limited to, pressure sensitive locking mechanisms that prevent actuation of the delivery means when a body part is incorrectly positioned within the gap in the housing.
- a trip-arm that projects into the space within the housing, can be provided to prevent actuation of the device unless a body part is contacting the arm, indicating proper positioning of the body part within the housing.
- the delivery system includes a housing 24 , having first and second substantially planar opposing arms, 26 and 28 , respectively, connected to each other at a closed end 30 of the housing.
- the opposing arms are open at an end 32 opposite from the closed end 30 , thereby defining a gap 34 into which a skin flap, ear, tail, fin, wing, or wing web can be inserted.
- a delivery means 36 is disposed on the first opposing arm, 26 , and allows for the delivery of pharmaceuticals to a body part inserted into the gap 34 .
- the delivery means can comprise any known delivery mechanism, such as conventional needle syringes, air injectors, jet injectors or particle injectors. As described above, delivery of the pharmaceutical is carried out within the confines of the housing 24 , and proceeds along a transverse direction relative to the plane of the opposing arms.
- the opposing arms are held together by a moveable, dynamic fastener 38 that allows the opposing arms 26 and 28 to move towards, or away from, each other about the fastener.
- the fastener can be pivotable, for example, hinged, thereby allowing the opposing arms to articulate about a pivot point supplied by the hinge.
- the fastener can comprise a slidable member that allows the opposing arms to move upwards-downwards relative to each other, such as wherein the fastener is compressible.
- Both pivotable and compressible fasteners allow the housing 24 to be positioned about a vertebrate subject's body part in an initial position, e.g., wherein the opposing arms 26 and 28 are spread apart from each other to define a maximum gap 34 .
- the opposing arms can be brought together to define a smaller gap, holding the body part in position for delivery of a pharmaceutical from the delivery means 36 .
- the ability to position and hold the targeted body part within the housing provides a high degree of control over the delivery of the pharmaceutical.
- movement of the opposing arms 26 and 28 toward each other actuates the delivery means 36 .
- the above-described safety features can be included with the delivery system 22 , such as by restricting the maximum gap size, and/or separating the delivery means from the open end of the housing, to prevent insertion of human appendages into the gap 34 , or accidental contact with the delivery means 36 .
- the pharmaceutical delivery systems 2 and 22 can also include one or more pads disposed on an inner surface of the first or second opposing arms of the housing.
- a delivery system 42 is shown with a pad 58 disposed on an opposing arm 48 of the housing 44 .
- the pad faces a delivery means 56 , and reduces the size of a gap defined by the surface of the pad, and the inner surface of a second opposing arm 46 .
- the pad 58 can be adjustably connected to the arm 48 , allowing movement of the pad relative to the arm so as to reduce or increase the size of the gap between the surface of the pad and the inner surface of the opposing arm.
- the adjustable pad can be used to maintain the position of a body part inserted into the housing for subsequent delivery of a pharmaceutical from the delivery means.
- the pad 58 can alternatively be inflatable, wherein the pad does not move relative to the arm 48 , but can increase in size to reduce the gap between the pad and the opposing arm.
- FIG. 6 a different delivery system 62 is depicted.
- the system is shown with a first pad 78 disposed on a first opposing arm 68 of the housing 64 .
- a second pad 80 is disposed on the second opposing arm 66 , and a delivery means 76 projects through the arm 66 and second pad 80 for delivery of pharmaceutical to a body part inserted within the housing as described above.
- the pads reduce the size of a gap defined by the inner surfaces thereof. Further, one, or both of the pads can be adjustably connected to the arm of the housing, allowing movement relative to the arm so as to reduce or increase the size of the gap.
- the delivery systems 2, 2', 22, 42 and/or 62 can further include means for applying tracking indicia on a body part inserted into the housing for delivery of the pharmaceutical.
- the housing can include one or more mechanisms for providing dye marks, tattoos, scars, brands, tags, ear or fin notches, or like indicia, to body parts inserted into the housing, thereby providing visual confirmation of pharmaceutical delivery in individual subjects.
- the tracking mechanism can be actuated by actuation of the delivery means, or individually actuated by appropriate controls.
- dyes or like materials can be included with a pharmaceutical composition delivered from the delivery system, thereby providing visual confirmation of pharmaceutical delivery.
- associated components such as a pharmaceutical supply and/or a source of motive force (e.g., compressed gas), can be carried in a backpack, or on the operator's belt.
- the associated components can be connected to the delivery system via an appropriate interface, thereby allowing for safe and simplified operation of the system.
- the delivery system housings can be reconfigured for use in delivery of a pharmaceutical to human subjects.
- the gap defined by the opposing jaws of the housing are sized to accommodate human body parts, for example arms of infants, children, adolescents or adult humans.
- the embodiments of the invention that comprise means for adjusting, positioning and holding inserted body parts are particularly well adapted for use in this context.
- the ability to position and hold the body part within the housing provides a high degree of control over delivery parameters, since targeted tissue can be substantially stabilized at a selected pressure, and a targeted delivery area maintained in position.
Landscapes
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Vending Machines For Individual Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
The opposing arms are open at an
Alternatively, the delivery means can be used for repeated delivery, in which case a controlled or metered supply of pharmaceutical and/or motive force (e.g., compressed gas) can be associated with the delivery system, either remotely or directly, by way of a suitable interface. Further, a plurality of discrete delivery means can be employed within the housing, such as wherein it is desirable to simultaneously deliver a number of different pharmaceuticals to the vertebrate subject using a single delivery system. In some embodiments, the delivery system can be configured to provide at least a partial vacuum with a body part inserted into the housing.
Claims (19)
- A pharmaceutical delivery system (2, 2', 22, 42, 62), comprising:(a) a housing (4, 4', 24, 44, 64) having first (6, 6', 26, 46, 66) and second (8, 8', 28, 48, 68) substantially planar opposing arms connected to each other on one end (10, 30) and open on an opposite end (12, 32), wherein the opposing arms define a gap (14, 34) into which a vertebrate body part can be inserted; and(b) delivery means (16, 16', 36, 56) disposed on an arm of the housing, wherein the delivery means is capable of delivering a pharmaceutical to a body part disposed within the gap in a transverse direction relative to the plane of the opposing arms and further characterised in that the delivery means is selected from the group consisting of a needle syringe, an air injector, a jet injector and a particle injector.
- The delivery system of claim 1, characterized in that the gap defined by the opposing arms can receive a skin flap, ear, tail, fin or wing of a vertebrate subject, but is small enough to reduce or eliminate the possibility of inserting a human finger into the gap.
- The delivery system of anyone of the preceding claims, characterized in that the delivery means is arranged on the arm such that the distance between the open end of the housing and the delivery means prevents contact between the-delivery means and any human appendage inserted into the gap.
- The delivery system of anyone of the preceding claims, characterized in that the delivery means is configured to deliver a pharmaceutical into the dermis, epidermis, or subcutaneous space of a body part placed within the gap defined by the opposing arms.
- The delivery system of claim 1 further comprising a pad (58, 78) disposed on an inner surface of an arm of the housing and facing the delivery means, characterized in that said pad and an inner surface of the opposing arm define a gap into which a vertebrate body part can be inserted.
- The delivery system of claim 5, characterized in that the pad is adjustably connected to the arm, thereby allowing movement of the pad relative to said arm so as to reduce or enlarge the gap defined by the pad and the inner surface of the opposing arm.
- The delivery system of anyone of claims 5-6, characterized in that the gap defined by the pad and the inner surface of the opposing arm can receive a skin flap, ear, tail, fin or wing of a vertebrate subject, but is small enough to reduce or eliminate the possibility of inserting a human appendage into the gap.
- The delivery system of anyone of claims 5-7, characterized in that the delivery means is configured to deliver a pharmaceutical into the dermis, epidermis, or subcutaneous space of a body part placed within the gap defined by the pad and the inner surface of the opposing arm.
- The delivery system of any one of the preceding claims, characterized in that the housing is inflatable and comprises means for communicating with a source of compressed gas.
- The delivery system of any one of the preceding claims further comprising means for applying tracking indicia to a body part inserted within the gap.
- The delivery system of claim 10, characterized in that the indicia is selected from the group consisting of a dye mark, a tattoo, a scar, a brand, a tag and an ear or fin notch.
- A pharmaceutical delivery system according to any one of the preceding claims wherein said first and second substantially planar opposing arms are held together at a dynamic fastener (38) disposed at the closed end (30) of the housing.
- A delivery system according to claim 12 wherein the delivery means is disposed on the first arm of the housing.
- The delivery system of claim 12 or claim 13, characterized in that the fastener is pivotable.
- The delivery system of any one of claims 12 to 14, characterized in that the arms can be moved toward, away from, each other about the fastener, thereby decreasing or increasing the size of the gap.
- The delivery system of claim 15, characterized in that movement of the arms toward each other actuates the delivery means.
- The delivery system of claim 12 when dependent on claim 5, characterized in that the pad is inflatable so as to reduce, or deflatable so as to enlarge, the gap defined by the pad and the inner surface of the opposing arm.
- A delivery system according to any one of the preceding claims wherein a second delivery means (20) is disposed on the other arm of the housing.
- A delivery system according to any one of the preceding claims when dependent on claim 5 wherein the delivery system further comprises a second pad (80) disposed on the other arm of the housing.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3638797P | 1997-01-24 | 1997-01-24 | |
US36387 | 1997-01-24 | ||
PCT/CA1998/000019 WO1998032397A1 (en) | 1997-01-24 | 1998-01-20 | Pharmaceutical delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0955947A1 EP0955947A1 (en) | 1999-11-17 |
EP0955947B1 true EP0955947B1 (en) | 2003-01-02 |
Family
ID=21888334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98900505A Expired - Lifetime EP0955947B1 (en) | 1997-01-24 | 1998-01-20 | Pharmaceutical delivery system |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0955947B1 (en) |
AR (1) | AR011431A1 (en) |
AU (1) | AU734703B2 (en) |
BR (1) | BR9808876A (en) |
CA (1) | CA2276414A1 (en) |
DE (1) | DE69810442D1 (en) |
NZ (1) | NZ336847A (en) |
WO (1) | WO1998032397A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW573428B (en) | 2001-03-15 | 2004-01-21 | Canon Kk | Image reading apparatus and illumination apparatus |
FR2970863B1 (en) * | 2011-02-01 | 2014-01-17 | Desvac | DEVICE FOR INOCULATING A VETERINARY PRODUCT IN THE WING OF A POULTRY |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1605763A (en) | 1926-11-02 | Garment retainer | ||
US3788315A (en) | 1971-04-20 | 1974-01-29 | S Laurens | Disposable cutaneous transjector |
US3853125A (en) | 1971-10-05 | 1974-12-10 | W Clark | Disposable needleless injector |
GB2120554B (en) * | 1982-05-19 | 1986-01-15 | Robert Ernest Patterson | Animal injection or drench gun with marker in the form of a gun |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
FR2599976A1 (en) * | 1986-06-16 | 1987-12-18 | Michel Pistor | Therapeutic, portable, completely self-contained, transdermic device provided with at least one member forming a needle or tip which gets through the cutaneous barrier |
IL88808A (en) * | 1988-12-27 | 1996-05-14 | Dermamed Ness Ziona | Apparatus for administering medicaments in veterinary applications |
US5059182A (en) * | 1989-04-12 | 1991-10-22 | David H. Laing | Portable infusion device |
CA2032148A1 (en) * | 1989-05-01 | 1990-11-02 | David J. Mckeddie | Medicated ear tag |
US5062830A (en) | 1990-04-04 | 1991-11-05 | Derata Corporation | Dry disposable nozzle assembly for medical jet injector |
US5441015A (en) * | 1991-08-20 | 1995-08-15 | Farley; Michael D. | Compression boot and method for treatment of injured limb |
-
1998
- 1998-01-20 WO PCT/CA1998/000019 patent/WO1998032397A1/en active IP Right Grant
- 1998-01-20 NZ NZ336847A patent/NZ336847A/en unknown
- 1998-01-20 AU AU55463/98A patent/AU734703B2/en not_active Ceased
- 1998-01-20 EP EP98900505A patent/EP0955947B1/en not_active Expired - Lifetime
- 1998-01-20 CA CA002276414A patent/CA2276414A1/en not_active Abandoned
- 1998-01-20 BR BR9808876-9A patent/BR9808876A/en not_active IP Right Cessation
- 1998-01-20 DE DE69810442T patent/DE69810442D1/en not_active Expired - Lifetime
- 1998-01-23 AR ARP980100304 patent/AR011431A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE69810442D1 (en) | 2003-02-06 |
CA2276414A1 (en) | 1998-07-30 |
AU734703B2 (en) | 2001-06-21 |
EP0955947A1 (en) | 1999-11-17 |
WO1998032397A1 (en) | 1998-07-30 |
BR9808876A (en) | 2000-10-03 |
AU5546398A (en) | 1998-08-18 |
AR011431A1 (en) | 2000-08-16 |
NZ336847A (en) | 2000-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0749758B1 (en) | Improvements related to injections | |
ES2316162T3 (en) | ADMINISTRATION OF AN INJECTABLE ANTIBIOTIC IN THE EAR OF AN ANIMAL. | |
CA2467569C (en) | Automatic poultry injection delivery apparatus | |
US11318006B2 (en) | Injection apparatus | |
US20030088207A1 (en) | Jet injector with hand piece | |
EP0686053A1 (en) | Apparatus and method for injecting a pharmaceutical preparation in solid form | |
KR20010013175A (en) | Intra-vaginal device for pigs | |
CA2386110C (en) | Intranasal delivery system | |
US20130239979A1 (en) | Animal restraint device and method | |
US20200297467A1 (en) | Intranasal administration device | |
CA2589852C (en) | Device for injecting a pharmaceutical active principle | |
EP0955947B1 (en) | Pharmaceutical delivery system | |
US9782243B2 (en) | Animal restraint device and method | |
AU712482B2 (en) | Injection dart system | |
CA2541985A1 (en) | Apparatus and method for nasal delivery of compositions to birds | |
MXPA99006744A (en) | Pharmaceutical delivery system | |
ES2275092T5 (en) | Procedure of administration of an injectable antibiotic in the ear of an animal | |
US5725497A (en) | Injection dart system | |
KR102467542B1 (en) | Animal Consecutive injector | |
Deviche et al. | Short‐term modulation of domestic pigeon (Columbia livia L.) behaviour induced by intraventricular administration of ACTH | |
KR102355484B1 (en) | Stimulant therapy device for neck and shoulder muscles | |
Smuts | Ketamine hydrochloride-A useful drug for the field immobilization of the Spotted hyaena Crocuta crocuta | |
KR102812701B1 (en) | Injection device for animals | |
CN116600739A (en) | Device for injecting fluids into birds | |
CA2417843C (en) | Administration of an injectable antibiotic in the ear of an animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990908 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE DE DK ES FR GB IT NL SE |
|
EL | Fr: translation of claims filed | ||
17Q | First examination report despatched |
Effective date: 20010619 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: METAMORPHIX INTERNATIONAL, INC. |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE DE DK ES FR GB IT NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030102 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT Effective date: 20030102 Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030102 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030102 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: 20030102 |
|
REF | Corresponds to: |
Ref document number: 69810442 Country of ref document: DE Date of ref document: 20030206 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030402 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030402 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030402 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030403 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030730 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20030402 |
|
EN | Fr: translation not filed | ||
26N | No opposition filed |
Effective date: 20031003 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1025495 Country of ref document: HK |